Aptevo Therapeutics Price Target | APVO View Price Target for APVO Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. APVO | Aptevo Therapeutics Inc. Analyst Estimates ... Nov 05, 2019 · Aptevo Therapeutics Inc. analyst estimates by MarketWatch. View APVO revenue estimates and earnings estimates, as well as analyst recommendations. APVO:NASDAQ CM Stock Quote - Aptevo Therapeutics Inc ... Stock analysis for Aptevo Therapeutics Inc (APVO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
The 3 analysts offering 12-month price forecasts for Aptevo Therapeutics Inc The current consensus among 3 polled investment analysts is to Buy stock in
Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Aptevo Therapeutics Inc - TheStreet - Stock Market Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Aptevo Therapeutics Inc. (APVO) Stock Analysis & News ... Get breaking news and analysis on Aptevo Therapeutics Inc. (APVO) stock, price quote and chart, trading and investing tools. Get breaking news and analysis on Aptevo Therapeutics Inc. (APVO) stock Aptevo Therapeutics Price Target | APVO View Price Target for APVO Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
Aptevo Therapeutics Inc. Common Stock (APVO) Stock Quotes ...
What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock Zacks Nov-08-19 09:00AM Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting GlobeNewswire +7.39% Is A Downturn Overdue? Denison Mines Corp. (NYSE:DNN ... Piper Jaffray also rated APVO as Resumed on October 05, 2017, with its price target of $6 suggesting that APVO could surge by 88.0% from its current share price. Even though the stock has been trading at $0.44/share, analysts expect it to down by -10.31% to reach $3.25/share.